In short
Clinical trials investigating RNMB2 are studying a pentavalent meningococcal vaccine in healthy children, toddlers, and infants. The main goals are to assess safety and the immune response after vaccination. These trials are in Phase 2 and focus on meningococcal immunization.
Key points
- RNMB2 is being studied in a Phase 2 clinical trial focused on meningococcal immunization. The trial includes healthy infants, toddlers, and children. Researchers are checking both safety and immune response after vaccination. They are measuring adverse events, injection site reactions, serious adverse events, and antibody levels in blood. The study also compares RNMB2 with other vaccines used for meningococcal and routine childhood protection.
Trial overview
The clinical trial for RNMB2 is studying an investigational pentavalent meningococcal vaccine, which means a vaccine designed to target five meningococcal groups. The study is focused on meningococcal immunization in healthy young participants.
The trial is designed to learn whether the vaccine is safe and whether it helps the immune system make a response against meningococcal disease. The study is authorised and is listed as Phase 2.
Who can participate
The study includes healthy children, toddlers, and infants. This means the trial is not focused on people who already have meningococcal disease, but on young people who are being vaccinated to help prevent it.
The brief summary shows three age stages: Stage 1 for children, Stage 2 for toddlers, and Stage 3 for infants. In the infant group, the study looks at responses after the second dose given at about 4 months of age and after the third dose at 12 to 15 months of age.
What is being measured
The main outcomes include unsolicited immediate adverse events, solicited injection site reactions, systemic reactions, unsolicited adverse events, and serious adverse events. These are used to understand how well the vaccine is tolerated and whether any safety problems appear during the study.
The trial also measures immune response using hSBA, which is a blood test that checks whether antibodies can help block meningococcal bacteria. For infants, the study measures antibody titers, seroresponse, and geometric mean titers against meningococcal groups A, C, W, and Y, as well as reference MenB strains before and after vaccination.
For children and toddlers, the same types of immune measures are also recorded, including antibody titers, seroresponse, and geometric mean titers against groups A, C, W, Y, and reference MenB strains. The study also checks how many participants reach certain antibody levels, including levels at or above the lower limit of quantification, which means the lowest level the test can measure reliably.
Trial design and comparators
This is an interventional trial, so participants receive study vaccines and comparison vaccines as part of the research plan. The interventions listed include RNMB2-related study vaccines and several comparator vaccines, such as MenQuadfi, Bexsero, Nimenrix, Prevenar 13, Hexyon, and RotaTeq.
The brief summary says the study compares the MenPenta vaccine formulations with comparator vaccines. This helps researchers see whether the immune response and safety profile of RNMB2 are similar to or different from the comparison vaccines.
Trial phase and status
The trial is in Phase 2, which usually means the study is still testing safety and early effectiveness signals rather than final approval-level results. The study status is Authorised, and the planned enrollment is 750 participants.
The trial is built to describe the safety profile of the vaccine formulations in healthy children, toddlers, and infants, and to describe immune responses after vaccination at different time points. The main focus is on whether the vaccine can produce measurable protection-related antibodies against meningococcal groups A, C, W, Y, and reference MenB strains.